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Background:
Tumor necrosis factor-alpha and other proinflammatory cytokines are becoming well recognized as key 
mediators in the pathogenesis of many types of neuropathic pain. Thalidomide has profound immunomodulatory 
actions in addition to their originally intended pharmacological actions. There has been debate on the analgesic 
efficacy of opioids in neuropathic pain. The aim of this study was to investigate the effect of thalidomide and 
morphine on a spinal nerve ligation model in rats. 
Methods: 
Male Sprague-Dawley rats weighing 100−120 g were used. Lumbar (L) 5 and 6 spinal nerve ligations were 
performed to induce neuropathic pain. For assessment of mechanical allodynia, mechanical stimulus using von 
Frey filament was applied to the paw to measure withdrawal threshold. The effects of intraperitoneal 
thalidomide (6.25, 12.5, 25 and 50 mg/kg, respectively) and morphine (3 and 10 mg/kg, respectively) were 
examined on a withdrawal threshold evoked by spinal nerve ligation. 
Results: 
After L5 and 6 spinal nerve ligation, paw withdrawal thresholds on the ipsilateral side were significantly 
decreased compared with pre-operative baseline and with those in the sham-operated group. Intraperitoneal 
thalidomide and morphine significantly increased the paw withdrawal threshold compared to controls and 
produced dose-responsiveness. 
Conclusions: 
Systemic thalidomide and morphine have antiallodynic effect on neuropathic pain induced by spinal nerve 
ligation in rat. These results suggest that morphine and thalidomide may be alternative therapeutic approaches 
for neuropathic pain. (Korean  J  Pain  2010;  23:  172-178)
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INTRODUCTION
    N europathic pain can be defined as pain caused or in-
i t i a t e d  b y  a  p r i m a r y  l e s i o n  o f  t h e  p e r i p h e r a l  o r  c e n t r a l 
nervous system, manifesting with sensory symptoms and 
signs [1]. It is associated with allodynia, hyperalgesia and 
spontaneous  pain  with  varying  intensity,  in  which  pain 
could be so severe that daily activities like wearing clothes 
m i g h t  b e  d i f f i c u l t .  N e u r o p a t h i c  p a i n  c a n  a l s o  d e c r e a s e  
q u a l i t y  o f  l i f e ,  c a u s e  p a t i e n t s  t o  w i t h d r a w  s o c i a l l y  a n d 
e m o t i o n a l l y ,  a n d  c a u s e  p r o b l e m s  w i t h  m o o d  a n d  s l e e p .  
Moreover, unrelieved pain inhibits respiration, decreases 
mobility,  and  decreases  patient  functional  status,  which 
may lead to iatrogenic events, including pneumonia, con-
stipation, and deep vein thrombosis [2]. 
    Medications primarily used for neuropathic pain gen-
e r a l l y  f a l l  i n t o  t h e  c a t e g o r i e s  o f  a n t i c o n v u l s a n t s ,  a n t i -
depressants,  opioids,  and  topical  agents.  The  current 
treatment options, however, are not effective enough to 
make the pain endurable and the response rate has been 
estimated at a 30% to 50% reduction in pain in up to 50% 
of patients [3].
    Recen tly, accum ulating e vidence has demonstrated that 
both microglia and astrocytes release a variety of proin-
flammatory cytokines including interleukin (IL)-1β, IL-6, 
and tumor necrosis factor (TNF-α), which play a major role 
in mediating and/or maintaining hyperalgesia and allodynia 
in inflammatory, as well as neuropathic pain [4-6]. 
    Thalidomide, a derivative of glutamic acid, was devel-
oped initially as a sedative and used for morning sickness 
until 1961 when its use was banned due to its association 
with major birth defects. It reappeared in clinical practice 
because of its immunomodulatory properties. Furthermore, 
investigations  into  the  mechanisms  underlying  thalido-
m i d e ' s  p h a r m a c o t h e r a p e u t i c  a c t i o n  h a v e  i n c r e a s e d  [ 7 , 8 ] , 
with its effects on the production and release of TNF-α 
being of notable importance. Thalidomide has been used 
i n  s e v e r a l  c u t a n e o u s  i n f l a m m a t o r y  d i s o r d e r s  ( e r y t h e m a  
nodosum leprosum in lepromatous leprosy, cutaneous lu-
pus erythem atosus, se v er e ap h tosis), can cers (r e lapsed/ 
refractory multiple myeloma) and inflammatory conditions 
[9]. Previous studies have shown that thalidomide inhibits 
the  inflammatory  hyperalgesia  in  rats  and  the  writhing 
nociceptive response in mice [10,11]. Thalidomide was found 
to be effective in animal models of neuropathic pain, such 
as chronic sciatic nerve injury (CCI) and Lumbar (L) 5 ven-
tral  root  transection  (VRT)  neuropathy  [12,13];  however, 
several human case reports and series have demonstrated 
mixed  results,  with  some  patients  having  dramatic  re-
sponses, especially in chronic intractable conditions such 
as complex regional pain syndrome [14,15].
    Opioids are among the most powerful analgesics in 
clinical use for the treatment of nociceptive pain, but data 
concerning  their  effectiveness  in  neuropathic  pain  has 
been controversial [16,17]. However, evidence now suggests 
that opioids are effective in relieving some pain symptoms 
in patients with neuropathic pain of primarily peripheral 
origin [18,19]. 
    In the present study, we investigated the antiallodynic 
effects of morphine and thalidomide in a spinal nerve liga-
tion rat model. 
MATERIALS  AND  METHODS 
1. Animal preparation
    All experiments followed the Guidelines on Ethical 
Standards for Investigation of Experimental Pain in Animals 
[20]. Male Sprague-Dawley rats weighing 100-120 g were 
used in all experiments. Animals were acclimated to the 
laboratory environment for 5-7 days before being used in 
the study. While in the home cage environment, animals were 
fed a standard rat diet and tap water. Room temperature 
was maintained at 20-23
oC with a 12:12 h light/dark cycle.
2. Animal model of neuropathic pain 
　　Neuropathic pain was evoked by spinal nerve ligation 
of experimental rats, as previously described [21]. Briefly, 
the left L5 and L6 spinal nerves of rats were isolated ad-
jacent to the vertebral column during sevoflurane anes-
thesia and tightly ligated with a 6-0 silk suture distal to 
the dorsal root ganglia. Care was taken to avoid injury of 
the L4 spinal nerve. Animals were considered to be in neu-
r o p a t h i c  p a i n  w h e n  t h e y  e x h i b i t e d  m e c h a n i c a l  a l l o d y n i a 
i.e., paw flinching behavior response to the application of 
a bending force of less than 4 g. Sham rats underwent 
identical surgical procedures at the same level, but the spi-
nal nerves were not ligated. Rats showing motor impair-
ment after surgery were killed immediately using overdose 
of sevoflurane. 
3. Drugs
    The following drugs were used in this study: thalido-174 Korean J Pain Vol. 23, No. 3, 2010
mide (Sigma Chemical Co., St. Louis, MO, USA) and mor-
p h i n e  s u l f a t e  ( S i g m a  A l d r i c h  C o . ,  S t .  L o u i s ,  M O ,  U S A ) . 
Thalidomide was dissolved in dimethyl sulfoxide (DMSO), 
and the solution was then diluted with saline to reduce the 
concentration of DMSO to 10%. Morphine was dissolved in 
normal saline. Both agents were intraperitoneally admini-
stered. The dose of thalidomide and morphine were decided 
based on previous studies using neuropathic pain models.
4. Assessment of mechanical allodynia
    Paw withdrawal threshold (PWT) in response to me-
chanical stimulation was measured using the up and down 
method  [22]  by  applying  calibrated  von  Frey  filaments 
(Stoelting, Wood Dale, IL, USA) from underneath the cage 
through openings in the mesh floor to the hindpaw. Rats 
were placed in a separate transparent plexus-glass cham-
ber with a wire mesh floor underneath and acclimated to 
the test chambers for 30 min. A series of eight von Frey 
filaments (0.4, 0.7, 1.2, 2.0, 3.6, 5.5, 8.5 and 15 g) were 
applied vertically to the plantar surface of the hindpaw for 
5  s  w h i l e  t h e  h a i r  w a s  b e n t .  B r i s k  w i t h d r a w a l  o r  p a w 
flinching  was  considered  as  positive  responses.  If  rat 
showed the positive response the less stiff filament was 
used for the next trial, or the stiffer one for the case with 
no withdrawal or licking. The cut-off value was determined 
as 15 g, where the PWT was 15 g if the rat did not show 
any withdrawal or licking response to the application of a 
15 g von Frey filament. Rats which did not show allodynia 
(less than 4 g) were excluded from this study.
5. Experimental paradigm
    On the day of testing (day 10 after spinal nerve liga-
tion), rats were allowed to acclimate to the testing cham-
ber for 30 min then allocated into experimental and control 
gr o u p s  f o r  t h e  t es t ed  d ru gs . C o n t r o l  s t u d i es  w e r e p e r-
formed using intraperitoneal saline or DMSO according to 
the solvent used for the tested drug. Animals were tested 
only once in this study, and the investigator was blind to 
the drug given. The effects of thalidomide (6.25, 12.5, 25, 
and 50 mg/kg) and morphine (3 and 10 mg/kg) were inves-
tigated  in  the  neuropathic  pain  state,  and  withdrawal 
t h r e s h o l d  w a s  d e t e r m i n e d  a t  3 0  m i n u t e s  a f t e r  i n t r a -
peritoneal administration of experimental drugs.
6. General behavior 
    F or the purpose of examining motor impairment by 
thalidomide and morphine, the highest dose of each drug 
u s e d  w a s  g i v e n  i n t r a p e r i t o n e a l l y  t o  1 0  a d d i t i o n a l  r a t s .  
Motor function was assessed by the righting reflex and 
p l a c i n g - s t e p p i n g  r e f l e x .  T h e  f o r m e r  w a s  e v a l u a t e d  b y  
placing  the  rat  horizontally  with  its  back  on  the  table, 
which  normally  gives  rise  to  an  immediate  coordinated 
twisting of the body to an upright position. The latter was 
evoked by drawing the dorsum of either hind paw across 
the edge of the table. Normally rats try to put the paw 
ahead into a position to walk. Pinna reflex and corneal re-
flex were also evaluated and judged as present or absent. 
7. Statistical analysis 
    Data are expressed as mean ± SEM. Time response 
data are presented as paw withdrawal threshold to me-
chanical stimulation, while dose-response data are pre-
sented as the percent of maximum possible effect (%MPE). 
Withdrawal threshold data from von Frey filament testing 
were converted to %MPE, according to the formula: %MPE 
= [(postdrug threshold − post-injured baseline thresh-
old) / (cutoff threshold − post-injured baseline threshold)] 
×  100.  To  analyze  the  50%  probability  PWT  data  and 
dose-responsiveness, one-way analysis of variance (ANOVA) 
with Scheffe multiple comparison test was used. P values 
of ＜ 0.05 were considered statistically significant.
RESULTS 
1. Time course for development of mechanical allodynia in 
spinal nerve-ligated rats
    Before spinal nerve ligation, PWT s ranged from 12 g 
t o  1 4  g .  A f t e r  L 5 ,  6  s p i n a l  n e r v e  l i g a t i o n ,  w i t h d r a w a l  
threshold of the nerve-ligated group was significantly re-
duced in comparison with that of the sham-ligated group, 
and this reduced threshold persisted f or 21 days. With-
drawal threshold of the sham group did not change during 
the observation period (Fig. 1).
2. Effect  of  intraperitoneal  thalidomide  on  mechanical 
withdrawal thresholds 
    Thalidomide significantly increased PWT compared to 
controls (Fig. 2A), and produced dose-responsiveness (Fig. 
2B). The lower dose of thalidomide (6.25 mg/kg) produced 
no significant reversal of the tactile allodynia, however the 
higher dose of thalidomide (12.5, 25 and 50 mg/kg, re-
spectively)  effectively  increased  mechanical  withdrawal JI Choi, et al / Thalidomide & Morphine on Neuropathic Pain 175
Fig. 2. Effects of intraperitoneal thalidomide on the hindpaw-withdrawal response to von Frey filament stimulation after spinal 
nerve ligation. Data are presented as withdrawal threshold (A) or percentage of maximal possible effect (%MPE, B). Each 
line or bar represents mean ± SEM of 5−7 rats. Control studies were performed using intraperitoneal DMSO. Thalidomide
produced a dose-dependent increase in withdrawal threshold. *P  ＜ 0.05, 
†P  ＜ 0.01 vs. control.
Fig. 1. Time course of the hindpaw-withdrawal response to
von Frey filament stimulation after spinal nerve ligation. 
Data are presented as withdrawal threshold (g). Each line 
represents mean ± SEM of 8 rats. BL: baseline withdrawal
threshold measured before spinal nerve ligation. Significant
differences between the spinal nerve-ligated and sham- 
ligated groups are indicated. *P ＜ 0.05, 
†P ＜ 0.01, 
‡P ＜
0.001 vs. sham.
threshold compared to vehicle.
3. Effect  of  intraperitoneal  morphine  on  mechanical 
withdrawal thresholds
    Morphine (3 and 10mg/kg, respectively) significantly in-
creased PWT compared to controls (Fig. 3A), and produced 
dose-responsiveness (Fig. 3B). 
4. General behavioral effects
    None of the experimental drug-treated rats showed 
any motor dysfunction, guarding or obvious change in mo-
tor activity when observed in their home cages. All rats 
remained alert during the experiment.
DISCUSSION 
    Neuropathic pain encompasses a myriad of painful 
disease states that are often hard to treat, especially with 
one single medication. There is no "gold standard" in regard 
to one medication for neuropathic pain. Some new medi-
cations have emerged during the past few years that help 
to a ugm en t th e arm am en tarium o f m edi ca ti o ns used in 
neuropathic  pain  [3].  Recently,  increasing  evidence  in-
dicates that glial cells, one of non-neuronal cells, also play 
an important role in the pathogenesis of neuropathic pain 
and the mechanism of neuropathic pain by nerv e injury. 
Neuropathic pain is newly regarded as complex and integral 
i n  t h e  i n t e r a c t i o n  o f  n e u r o n a l  a n d  n o n - n e u r o n a l  c e l l s  
[4-6].  Not  only  neurotransmitters  from  neurons  at  the 
synapses, but also many cytokines released from glial cells 
are involved in the development of hyperalgesia and allo-
dynia in inflammatory as well as neuropathic pain. In addi-
tion, much research indicates that proinflammatory cyto-
kines such as TNF-α, IL-1β and IL-6 are major elements 
contributing  to  development  and  maintenance  of  the 
pathological state of pain [6,23]; consequently, they have 176 Korean J Pain Vol. 23, No. 3, 2010
Fig. 3. Effects of intraperitoneal morphine on the hindpaw-withdrawal response to von Frey filament stimulation after spinal
nerve ligation. Data are presented as withdrawal threshold (A) or percentage of maximal possible effect (%MPE, B). Each 
line or bar represents mean ± SEM of 5−7 rats. Control studies were performed using intraperitoneal saline. Morphine 
produced a dose-dependent increase in withdrawal threshold. *P ＜ 0.05, 
†P  ＜ 0.01 vs. control.
been proposed as therapeutic targets [24]. 
    Thalidomide has profound immunomodulatory actions 
in addition to its originally intended pharmacological actions. 
Thalidomide is currently approved by the US Food and Drug 
Administration in conjunction with dexamethasone in newly 
diagnosed multiple myeloma, and in the acute treatment 
of cutaneous manifestations of erythema nodosum lep-
rosum, as well as in maintenance therapy for its prevention 
and suppression.
    In the present study, intraperitoneal thalidomide sig-
nificantly increased PWT compared to control and produced 
dose-responsiveness. The lower dose of thalidomide (6.25 
mg/kg) produced no significant reversal of tactile allodynia, 
but the higher dose of thalidomide (12.5, 25 and 50 mg/kg, 
respectively)  effectively  increased  mechanical  withdrawal 
threshold compared to vehicle.
    Although thalidomide and its analogues have broad- 
spectrum properties, their major mode of action is the in-
hibition  of  TNF-α  synthesis.  Thalidomide  reduces  syn-
thesis of TNF-α in cultures of lipopolysaccharide-stimulated 
h u m a n  m i c r o g l i a l  c e l l s  [ 2 5 ] ,  a n d  a l s o  m o d u l a t e s  T N F - α 
production by several mechanisms, for example, by en-
hancing TNF-α mRNA degradation [26] or by binding to 
a1-acid glycoprotein [27]. Thalidomide was also found to 
be effective in animal models by inhibiting TNF-alpha pro-
duction [10-13]. Previous studies have shown that thalido-
mide inhibits inflammatory hyperalgesia in rats and the 
writhing nociceptive response in mice as a possible con-
sequence of inhibition of TNF-α production [10,11]. It has 
also  been  reported  that  thalidomide  reversed  and  pre-
vented the hyperalgesia by inhibiting TNF-α production in 
chronic sciatic nerve injury and L5 VRT neuropathy, re-
spectively [12,13]. However, in other studies [13,28], thali-
domide was only effective when given preemptively, i.e., 
before manifestation of the pain related symptom. However, 
in our study intraperitoneal injection of thalidomide effec-
tively attenuated mechanical allodynia when it was applied 
at day 10 after surgery. This discrepancy may be related 
t o  d i f f e r e n t  a n i m a l  m o d e l s  a n d  e x p e r i m e n t a l  m e t h o d s .  
Also, it has also been reported that when applied 7 days 
after surgery thalidomide was still capable of inhibiting up-
regulation of TNF-α in L5 VRT neuropathy [13]. Thus, it 
is most likely that the antinociceptive effect of thalidomide 
in this present study comes from the interruption of TNF-
α production. The pharmacological properties of thalido-
m id e asi d e fr om the ir imm un om od u latory capa cit y co ul d 
also explain the effects observed in our study. The seda-
tive-hypnotic  effect  of  thalidomide  was  suggested  as 
mediated via interruption or modulation of serotonin's ac-
tions within the CNS. However, rats injected with thalido-
mide did not show any sedative state at the dose of max-
imum analgesic effect during the behavioral test. 
    V arious studies have reported reduced antinociceptive 
e f f i c a c y  o f  m o r p h i n e  i n  a n i m a l  m o d e l s  o f  p e r i p h e r a l  o r JI Choi, et al / Thalidomide & Morphine on Neuropathic Pain 177
central nerve injury. However, conflicting results regarding 
t h e  e f f i c a c y  o f  o p i o i d s  o n  n e u r o p a t h i c  p a i n  i n  d i f f e r e n t 
neuropathic animal models have been reported. While sys-
temic administration of morphine attenuates allodynia and 
hyperalgesia in chronic constriction injury and spinal nerve 
ligation (SNL) models [29,30], intrathecal morphine is ap-
parently ineffective [29,31]. In contrast, intrathecal mor-
phine dose-dependently reversed mechanical allodynia in 
a rat model of central pain, whereas systemic morphine 
had little effect on this measure [32]. Recently, these find-
ings have been challenged by Zhao et al. [33] who reported 
antiallodynic effects of both systemic and intrathecally ad-
ministered morphine in the SNI, SNL and SCI animal mod-
els of neuropathic pain. These results indicate the efficacy 
of opioids in neuropathic pain is variable and seems to de-
pend on several factors (e.g., the kind of nerve injury and 
the route of drug administration). In this study, the 3 and 
10  mg/kg  doses  of  systemic  morphine  significantly  in-
creased PWT compared to vehicle. Our study indicates that 
systemic morphine produces antiallodynic effects in SNL 
rats, which is consistent with previous reports [30,33]. Our 
results further support the efficacy of opioid receptor ago-
n i s t s  i n  a l l e v i a t i n g  s i g n s  o f  n e u r o p a t h i c  p a i n  i n  a n i m a l  
models of peripheral nerve injury. 
    In this present study, intraperitoneal thalidomide and 
morphine significantly increased PWT compared to control 
and produced dose-responsiveness. However, similar studies 
on various animals are required to obtain a reliable over-
sight of the effect of thalidomide on peripheral and central 
nerve injury-induced neuropathic pain in a clinical setting. 
    In conclusion, systemic morphine and thalidomide hav e 
antiallodynic effects on neuropathic pain induced by SNL 
in rats. These results suggest that morphine and thalido-
mide may be an alternative therapeutic approach for neu-
ropathic pain. 
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